HC Deb 05 April 1976 vol 909 cc55-6W
Mr. Pavitt

asked the Secretary of State for Social Services if she is satisfied with the clinical data given in the promotional material issued by the manufacturers of talampicillin, in view of the danger to patients where the renal and hepatic functions are impaired; why the new drug is being licensed; and if she will make a statement.

Dr. Owen

I consider that the clinical data given in the promotional material for this product, which includes a precaution that it is not recommended for patients with severe renal or hepatic

NHS £ million Social Security £ million Total £ million Percentage of GNP
1949 434 625 1,059 9.5
1950 478 660 1,138 9.7
1951 499 689 1,188 9.1
1952 511 805 1,316 9.4
1953 527 893 1,420 9.4
1954 537 900 1,437 9.0
1955 579 993 1,572 9.2
1956 633 1,062 1,695 9.2
1957 686 1,117 1,803 9.2
1958 727 1,345 2,072 10.1
1959 789 1,450 2,239 10.4
1960 861 1,488 2,349 10.3
1961 930 1,628 2,558 10.4
1962 971 1,744 2,715 10.6
1963 1,035 1,988 3,023 11.1
1964 1,130 2,099 3,229 10.9
1965 1,275 2,408 3,683 11.6
1966 1,401 2,577 3,978 11.9
1967 1,552 2,900 4,452 12.6
1968 1,688 3,340 5,028 13.3
1969 1,767 3,571 5,338 13.4
1970 2,018 3,923 5,941 13.6
1971 2,290 4,309 6,599 13.4
1972 2,643 5,119 7,762 14.0
1973 2,990 5,532 8,522 13.2
1974 3,819 6,845 10,664 14.4

Mrs. Chalker

asked the Secretary of State for Social Services what increased

impairment, is satisfactory. There is no known evidence of danger to these patients but because the proper metabolism and excretion of talampicillin depends on adequate liver and renal function it was considered appropriate by the manufacturer to include the above precaution. Product licences have been granted on the advice of the Committee on Safety of Medicines which carefully considered all the available evidence relating to the safety and efficacy of the product.

Forward to